T1DM is an autoimmune disorder\u00a0characterized by the destruction of beta cells, resulting in an absolute deficiency of insulin secretion. Conventional medicine holds that patients require lifelong insulin injections. However, Professor An\u2019s team employed the\u00a0HIM model combining holistic traditional Chinese medicine (TCM), orthomolecular medicine, functional medicine, and lifestyle medicine focused on immune blockade and metabolic balance, alongside endocrinology-specialized precision remote digital healthcare, to successfully restore islet function and enable insulin discontinuation.<\/p>\n
The core of this treatment protocol lies in multidisciplinary collaboration, including precision diagnostics using mass spectrometry platforms to identify the immunological causes of T1DM for targeted etiological treatment; immune regulation through molecular nutrition and TCM to modulate abnormal immune responses and reduce autoimmune attacks on pancreatic islet cells; metabolic repair by improving the body\u2019s microenvironment and promoting islet function recovery via TCM acupuncture, herbal medicine, and nutritional interventions; and precision monitoring that employs artificial intelligence to dynamically analyze patients\u2019 blood glucose and immune markers, allowing personalized adjustments to treatment strategies. Patients typically require only 3 to 5 days of hospitalization before discharge.<\/p>\n
\uff08Professor An Chiying inspects patients with type 1 diabetes\uff09 <\/p>\n
Clinical Data: 24 Patients Discontinued Insulin Therapy<\/strong><\/p>\n Over a two-year clinical observation period, the team intervened in 70 patients with T1DM, among whom 24 patients (34%) completely discontinued insulin use. These patients maintained stable blood glucose levels (HbA1c <\/p>\n Story Continues <\/p>\n Professor An Chiying emphasized, \u201cFunctional cure refers to the partial restoration of islet function sufficient to meet normal metabolic demands, achieved through immune blockade, intestinal mucosal repair, and gut microbiota reconstruction. Patients diagnosed early with T1DM who have a C-peptide level above 0.5 ng\/ml can stop insulin, while those with insufficient islet function can significantly reduce insulin dosage once blood glucose levels are stabilized.\u201d<\/p>\n National Academician\u2019s Evaluation: Pioneering a New Treatment Paradigm<\/strong><\/p>\n Academician Fan Daiming of the Chinese Academy of Engineering (CAE) and pioneer of HIM in China commented, \u201cThe results achieved by this Chinese team challenge the traditional view that T1DM requires lifelong medication. The synergistic effects of HIM deserve the attention of peers worldwide and open a new clinical treatment paradigm for T1DM.\u201d<\/p>\n Background<\/strong><\/p>\n There are approximately 9 million T1DM patients globally. Traditional treatment costs exceed RMB 10,000 annually, and patient prognoses remain unsatisfactory with uncontrollable risks of complications. The widespread adoption of HIM health management programs could significantly reduce both the financial and health burdens on patients.<\/p>\n Contact Information:\u00a0Shenzhen Hengsheng Hospital\u00a0Chronic Disease Integrative Medicine Center\/Diabetes Naturopathic\u00a0Center.<\/p>\n Shenzhen Hengsheng Hospital Chronic Disease Integrative Medicine Center\/Diabetes Naturopathic Center<\/p>\n Company Name: ShanghaiFosunGroup-ShenzhenHangSengHospital Email: kefu@hsyy.com.cn<\/p>\n
Contact Person: Anchiying
Phone: +86-755-27796031
City: Shenzhen
Website:\u00a0https:\/\/www.hsyy.com.cn\/<\/a><\/p>\n